Quick Answer
Immunovant, Inc. reported Diluted EPS of $2.73 per share (loss) for fiscal year 2025.
Immunovant, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.73 | -45.2% |
| 2024 | -$1.88 | -9.9% |
| 2023 | -$1.71 | -19.6% |
| 2022 | -$1.43 | -17.2% |
| 2021 | -$1.22 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.61 | +19.7% | +16.4% |
| September 30, 2025 | -$0.73 | +1.4% | -2.8% |
| June 30, 2025 | -$0.71 | -18.3% | +6.6% |
| December 31, 2024 | -$0.76 | -111.1% | -2.7% |
| September 30, 2024 | -$0.74 | -64.4% | -23.3% |
| June 30, 2024 | -$0.60 | -5.3% | -66.7% |
| December 31, 2023 | -$0.36 | +26.5% | +20.0% |
| September 30, 2023 | -$0.45 | -9.8% | +21.1% |
- Immunovant, Inc. showed a decrease of -45.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Immunovant, Inc.’s diluted eps has declined by 123.8% (from $1.22 per share (loss) to $2.73 per share (loss)).
- The most recent figure is from Immunovant, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on May 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: